Herpes Zoster and Post-herpetic Neuralgia
详细信息    查看全文
Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. Provides an overview of the burden of HZ in different parts of the world.PubMedCentral CrossRef PubMed
2.Yawn BP et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9.CrossRef PubMed
3.Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol. 2003;70 Suppl 1:S9–14.CrossRef PubMed
4.Brisson M et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127(2):305–14.PubMedCentral PubMed
5.Fruergaard P et al. The diagnoses of patients admitted with acute chest pain but without myocardial infarction. Eur Heart J. 1996;17(7):1028–34.CrossRef PubMed
6.Hassan I, Donohue JH. Herpes zoster mistaken for biliary colic and treated by laparoscopic cholecystectomy: a cautionary case report. Surg Endosc. 1996;10(8):848–9.CrossRef PubMed
7.Staikov I et al. Herpes zoster as a systemic disease. Clin Dermatol. 2014;32(3):424–9.CrossRef PubMed
8.Lam FC, Law A, Wykes W. Herpes zoster ophthalmicus. BMJ. 2009;339:b2624.CrossRef PubMed
9.Ittner EA, Bhakhri R, Newman T. Necrotising herpetic retinopathies: a review and progressive outer retinal necrosis case report. Clin Exp Optom. 2015;18(10):12284.
10.Coulson S et al. Prognostic factors in herpes zoster oticus (Ramsay Hunt syndrome). Otol Neurotol : Off Publ Am Otol Soc, Am Neurotol Soc Eur Acad Otol Neurotol. 2011;32(6):1025–30.CrossRef
11.Salazar R et al. Varicella zoster virus ischemic optic neuropathy and subclinical temporal artery involvement. Arch Neurol. 2011;68(4):517–20.PubMedCentral CrossRef PubMed
12.Kang SH, Song HK, Jang Y. Zoster-associated segmental paresis in a patient with cervical spinal stenosis. J Int Med Res. 2013;41(3):907–13.CrossRef PubMed
13.Namekawa M et al. Segmental zoster paresis of the right shoulder. Intern Med. 2013;52(24):2839.CrossRef PubMed
14.Yaszay B, Jablecki CK, Safran MR. Zoster paresis of the shoulder. Case report and review of the literature. Clin Orthop Relat Res. 2000;377:112–8.CrossRef PubMed
15.Lin CM et al. An unusual cause of dyspnea in a patient with cervical herpes zoster. J Clin Neurosci: Off J Neurosurg Soc Australasia. 2012;19(4):608–9.CrossRef
16.Imafuku S et al. Herpes zoster-associated voiding dysfunction in hematopoietic malignancy patients. Int J Dermatol. 2008;47(1):36–9.CrossRef PubMed
17.Jakubovicz D, Solway E, Orth P. Herpes zoster: unusual cause of acute urinary retention and constipation. Can Fam Phys Med Fam Can. 2013;59(3):e146–7.
18.•
Umezawa Y et al. Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation. Transpl Infect Dis : Off J Transplantat Soc. 2014;16(2):195–202. Descriptive study of disseminated HZ suggests that delayed antiviral treatment promotes dissemination in HSCT recipients.CrossRef
19.Stratman E. Visceral zoster as the presenting feature of disseminated herpes zoster. J Am Acad Dermatol. 2002;46(5):771–4.CrossRef PubMed
20.Rubben A, Baron JM, Grussendorf-Conen EI. Routine detection of herpes simplex virus and varicella zoster virus by polymerase chain reaction reveals that initial herpes zoster is frequently misdiagnosed as herpes simplex. Br J Dermatol. 1997;137(2):259–61.CrossRef PubMed
21.Cholongitas E, Ilonidis G. Transmission of varicella-zoster virus originating from a patient with localized herpes zoster: implications for infection control? Am J Infect Control. 2010;38(8):669–70.CrossRef PubMed
22.•Li Q, et al. Antiviral treatment for preventing postherpetic neuralgia. The Cochrane database of systematic reviews. 2009;(2):p. CD006866. Metanalysis that addresses the role of antiviral therapy in PHN prevention
23.Drolet M et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain : Off J Am Pain Soc. 2010;11(11):1211–21.CrossRef
24.Kawai K et al. Predictors of postherpetic neuralgia in patients with herpes zoster: a pooled analysis of prospective cohort studies from North and Latin America and Asia. Int J Infect Dis: IJID : Off Publ Int Soc Infect Dis. 2015;34:126–31.
25.•Johnson RW et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37. Quantifies impact of HZ and PHN on quality of life.PubMedCentral CrossRef PubMed
26.Massengill JS, Kittredge JL. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. J Pain Res. 2014;7:125–32.PubMedCentral CrossRef PubMed
27.••Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84(3):274–80. Overview of clinical presentation, management, and prevention of HZ and PHN.PubMedCentral CrossRef PubMed
28.Irving G. Once-daily gastroretentive gabapentin for the management of postherpetic neuralgia: an update for clinicians. Ther Adv Chronic Dis. 2012;3(5):211–8.PubMedCentral CrossRef PubMed
29.Markley HG et al. Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN). Clin J Pain. 2015;31(1):58–65.PubMedCentral CrossRef PubMed
30.•Coplan PM et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain : Off J Am Pain Soc. 2004;5(6):344–56. Useful tool to perform baseline assessment of HZ pain and assess response to therapy.CrossRef
31.Benzon HT et al. Evidence-based case report: the prevention and management of postherpetic neuralgia with emphasis on interventional procedures. Reg Anesth Pain Med. 2009;34(5):514–21.CrossRef PubMed
32.••Oxman MN et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84. Landmark study that was the basis of the licensure of the zoster vaccine.CrossRef PubMed
33.••Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep : Morb Mortal Wkly Rep Recomm Rep/ Cent Dis Control. 2008;57(RR-5):1–30. Quiz CE2-4. Guidelines for the use of the zoster vaccine.
34.Williams WW et al. Vaccination coverage among adults, excluding influenza vaccination—United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(4):95–102.PubMed
35.•Lal H et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96. Results of a study of a promising new inactivated zoster vaccine.CrossRef PubMed
  • 作者单位：Priya Sampathkumar (1)

    1. Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA
  • 刊物主题：Geriatrics/Gerontology; Medicine/Public Health, general; Psychopharmacology; Pain Medicine; Neurology; Rheumatology;
  • 出版者：Springer US
  • ISSN：2162-4941
    • 文摘
    Herpes zoster (HZ), which is commonly referred to as shingles, is a syndrome of pain and skin rash that is caused by reactivation of varicella zoster virus (VZV). After primary varicella infection (chicken pox), the virus goes into latency in the spinal cord ganglia. The virus is reactivated when immunity to VZV declines as happens with aging or immunosuppression. The risk of zoster increases steeply after the age of 50 years. Post-herpetic neuralgia (PHN), defined as pain persisting more than 3 months after the skin rash has healed, is a serious consequence of HZ that is difficult to treat and significantly impacts quality of life. Early recognition and treatment of HZ is helpful in reducing acute symptoms but may not impact PHN. A live, attenuated zoster vaccine (Zostavax, Merck and Co. Inc., Whitehouse Station, NJ, USA) is currently recommended for adults over the age of 60 to prevent HZ and PHN. The vaccine reduces the incidence of HZ by 50 % and PHN by 67 %. It is safe and is well tolerated; most common side effects of the vaccine are minor local injection site reactions and headache. Despite being available since 2006, the vaccine remains underutilized, and by most recent estimates, less than one quarter of individuals over the age of 60 have been vaccinated. It is a live viral vaccine and is therefore contraindicated in immunocompromised individuals who comprise the patient population at highest risk of zoster. Studies are currently underway of viral subunit vaccines, and preliminary data suggests that they may be more efficacious in the elderly.
    NGLC 2004-2010.National Geological Library of China All Rights Reserved.
    Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
    For exchange or info please contact us via email.